Physician profile
Julia S Kimbrough
NPI 1619417581
$4,188.71
in general payments reported to CMS, 2019-2025
41 companies · $809 in 2025
The $809 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $905 · 2022: $970 · 2023: $819 · 2024: $686 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,313.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $956.44 | 2021-2025 | |
| Novo Nordisk INC | $870.84 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $452.51 | 2021-2025 | |
| Lilly USA, LLC | $175.64 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $159.63 | 2022-2024 | Shingrix, Arexvy |
| Boston Scientific Corporation | $142.82 | 2023-2025 | Farapulse, Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.20 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $118.10 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $115.35 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $103.47 | 2021-2024 | |
| Astellas Pharma US INC | $99.91 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $98.47 | 2022-2025 | Airsupra, Farxiga |
| Optinose US, INC. | $61.00 | 2022-2025 | |
| Amgen INC. | $54.28 | 2021-2025 | Evenity, Prolia |
| Dexcom, INC. | $45.97 | 2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Kimbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.